Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Activist hedge fund investor Elliott Investment Management has bought over a $1 billion stake in BioMarin as the biotech grapples with a leadership change and disappointing sales of its hemophilia A gene therapy.
Newer hiring models based on skills applicants have learned and their general potential for growth could avoid the drawbacks of relying on degrees and experience.
Social media campaigns may have been one factor that prompted Johnson & Johnson and Danaher to make a TB treatment and a test more accessible in low- and middle-income countries.
A combination of Gilead Sciences’ domvanalimab and Arcus Biosciences’ zimberelimab, along with chemo, has shown an “encouraging” overall response rate in a mid-stage study.
Cell and gene therapy represents the most promising breakthrough in cancer treatment for decades, but it comes with a hefty price tag. Here’s how to drive costs down.
Although it hit primary and secondary endpoints in a Phase II study, Ventyx Biosciences concluded that the results weren’t strong enough to face the stiff competition for the indication.
Merz Therapeutics announced today the presentation of data from 10 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2022
Merz Therapeutics announced today its U.S. organization has made a $100,000 donation to the University of North Carolina (UNC) Health Foundation
18 accepted abstract presentations provide important updates and data on XEOMIN. Abstracts also published in Toxicon, a peer-reviewed interdisciplinary journal on toxins
BioSpace has published its annual 2024 Best Places to Work list.
For $80 million upfront and the promise of more than $1.2 billion in milestones, Novartis has bought the global rights to develop an oral HDAC6 inhibitor from Chong Kun Dang Pharmaceutical.
The cell therapy-focused biotech will use most of the net proceeds from its initial public offering to fund Phase II clinical trials for its lead program, a novel CAR T-cell candidate.